Apoptosis In Targeted Therapy Responses. The Role of BIM

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 519-542

  Faber, Anthony C ^a   Ebi, Hiromichi ^a   Costa, Carlotta ^a   Engelman, Jeffrey A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; BIM; Intrinsic resistance; Oncogene addicted cancer; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; B RAF KINASE INHIBITOR; BH3 PROTEIN; BIM PROTEIN; CISPLATIN; CRIZOTINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LAPATINIB; MICRORNA; NAVITOCLAX; OBATOCLAX; PACLITAXEL; TRASTUZUMAB; VEMURAFENIB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; EPIGENETICS; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84865844587     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00016-6     Document Type: Chapter

References (88)

1. Bachmann P.S., Piazza R.G., Janes M.E., Wong N.C., Davies C., Mogavero A., et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010, 116(16):3013-3022.
2. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology 1999, 26(4 Suppl. 12):78-83.
3. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(52):20932-20937.
4. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology 2005, 23(31):8081-8092.
5. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(52):22299-22304.
6. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005, 17(3):393-403.
7. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. The New England Journal of Medicine 2010, 363(18):1734-1739.
8. Corcoran R.B., Dias-Santagata D., Bergethon K., Iafrate A.J., Settleman J., Engelman J.A. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signaling 2010, 3(149):ra84.
9. Corcoran R.B., Settleman J., Engelman J.A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011, 2(4):336-346.
10. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Medicine 2007, 4(10):1669-1679. (discussion 1680).
11. Cragg M.S., Jansen E.S., Cook M., Harris C., Strasser A., Scott C.L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. The Journal of Clinical Investigation 2008, 118(11):3651-3659.
12. Dai D.L., Wang Y., Liu M., Martinka M., Li G. Bim expression is reduced in human cutaneous melanomas. The Journal of Investigative Dermatology 2008, 128(2):403-407.
13. De Bruyne E., Bos T.J., Schuit F., Van Valckenborgh E., Menu E., Thorrez L., et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 2010, 115(12):2430-2440.
14. Del Gaizo Moore V., Letai A. BH3 profiling - measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Letters 2012.
15. Deng J., Carlson N., Takeyama K., Dal Cin P., Shipp M., Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12(2):171-185.
16. Deng J., Shimamura T., Perera S., Carlson N.E., Cai D., Shapiro G.I., et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Research 2007, 67(24):11867-11875.
17. Druker B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Seminars in Hematology 2001, 38(3 Suppl. 8):9-14.
18. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996, 2(5):561-566.
19. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of Clinical Investigation 2011, 121(11):4311-4321.
20. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(16):6164-6169.
21. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(10):3788-3793.
22. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
23. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics & Development 2008, 18(1):73-79.
24. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29(16):2346-2356.
25. Erlacher M., Labi V., Manzl C., Bock G., Tzankov A., Hacker G., et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. Journal of Experimental Medicine 2006, 203(13):2939-2951.
26. Essafi A., Fernandez de Mattos S., Hassen Y.A., Soeiro I., Mufti G.J., Thomas N.S., et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005, 24(14):2317-2329.
27. Ewings K.E., Wiggins C.M., Cook S.J. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 2007, 6(18):2236-2240.
28. Faber A.C., Corcoran R.B., Ebi H., Sequist L.V., Waltman B.A., Chung E., et al. BIM expression in treatment naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery 2011, 1(4):352-365.
29. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(46):19503-19508.
30. Faber A.C., Wong K.K., Engelman J.A. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010, 9(5):851-852.
31. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine 2010, 363(9):809-819.
32. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(7):909-916.
33. Garofalo M., Romano G., Di Leva G., Nuovo G., Jeon Y.J., Ngankeu A., et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature Medicine 2012, 18(1):74-82.
34. Gavathiotis E., Suzuki M., Davis M.L., Pitter K., Bird G.H., Katz S.G., et al. BAX activation is initiated at a novel interaction site. Nature 2008, 455(7216):1076-1081.
35. Gillings A.S., Balmanno K., Wiggins C.M., Johnson M., Cook S.J. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. The FEBS Journal 2009, 276(21):6050-6062.
36. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of Clinical Investigation 2008, 118(7):2609-2619.
37. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
38. Huang H., Tindall D.J. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochimica et Biophysica Acta 2011, 1813(11):1961-1964.
39. Inomata M., Tagawa H., Guo Y.M., Kameoka Y., Takahashi N., Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood 2009, 113(2):396-402.
40. Jackman D.M., Yeap B.Y., Sequist L.V., Lindeman N., Holmes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clinical Cancer Research 2006, 12(13):3908-3914.
41. Kan T., Sato F., Ito T., Matsumura N., David S., Cheng Y., et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009, 136(5):1689-1700.
42. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Science Translational Medicine 2012, 4(120). 120ra117.
43. Kim H., Tu H.C., Ren D., Takeuchi O., Jeffers J.R., Zambetti G.P., et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Molecular Cell 2009, 36(3):487-499.
44. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2005, 352(8):786-792.
45. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(40):14907-14912.
46. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine 2010, 363(18):1693-1703.
47. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(21):7665-7670.
48. Ley R., Balmanno K., Hadfield K., Weston C., Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. The Journal of Biological Chemistry 2003, 278(21):18811-18816.
49. Luciano F., Jacquel A., Colosetti P., Herrant M., Cagnol S., Pages G., et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003, 22(43):6785-6793.
50. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2004, 350(21):2129-2139.
51. Mauro M.J., Druker B.J. Chronic myelogenous leukemia. Current Opinion in Oncology 2001, 13(1):3-7.
52. Meng J., Fang B., Liao Y., Chresta C.M., Smith P.D., Roth J.A. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One 2010, 5(9):e13026.
53. Merino D., Strasser A., Bouillet P. Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene 2011.
54. Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007, 109(1):271-280.
55. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine 2012, 18(4):521-528.
56. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(49):19512-19517.
57. Ni Chonghaile T., Sarosiek K.A., Vo T.T., Ryan J.A., Tammareddi A., Moore Vdel G., et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334(6059):1129-1133.
58. Paraiso K.H., Xiang Y., Rebecca V.W., Abel E.V., Chen Y.A., Munko A.C., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Research 2011, 71(7):2750-2760.
59. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480(7377):387-390.
60. Pricl S., Fermeglia M., Ferrone M., Tamborini E. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Molecular Cancer Therapeutics 2005, 4(8):1167-1174.
61. Puissant A., Grosso S., Jacquel A., Belhacene N., Colosetti P., Cassuto J.P., et al. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB Journal 2008, 22(6):1894-1904.
62. Qi J., McTigue M.A., Rogers A., Lifshits E., Christensen J.G., Janne P.A., et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Research 2011, 71(3):1081-1091.
63. Qin Y., Chen S., Jiang B., Jiang Q., Jiang H., Li J., et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Annals of Hematology 2011, 90(1):47-52.
64. Rahmani M., Anderson A., Habibi J.R., Crabtree T.R., Mayo M., Harada H., et al. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 2009, 114(20):4507-4516.
65. Rexer B.N., Ham A.J., Rinehart C., Hill S., Granja-Ingram Nde M., Gonzalez-Angulo A.M., et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011, 30(40):4163-4174.
66. Richter-Larrea J.A., Robles E.F., Fresquet V., Beltran E., Rullan A.J., Agirre X., et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010, 116(14):2531-2542.
67. San Jose-Eneriz E., Agirre X., Jimenez-Velasco A., Cordeu L., Martin V., Arqueros V., et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. European Journal of Cancer 2009, 45(10):1877-1889.
68. Sequist L.V., Heist R.S., Shaw A.T., Fidias P., Rosovsky R., Temel J.S., et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology 2011, 22(12):2616-2624.
69. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26(15):2442-2449.
70. Shao Y., Aplin A.E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Research 2010, 70(16):6670-6681.
71. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Journal of Clinical Oncology 2009, 27(26):4247-4253.
72. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet Oncology 2011, 12(11):1004-1012.
73. Smalley K.S., Flaherty K.T. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. British Journal of Cancer 2009, 100(3):431-435.
74. Tagawa H., Karnan S., Suzuki R., Matsuo K., Zhang X., Ota A., et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005, 24(8):1348-1358.
75. Takezawa K., Okamoto I., Nishio K., Janne P.A., Nakagawa K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clinical Cancer Research 2011, 17(8):2140-2148.
76. Tan T.T., Degenhardt K., Nelson D.A., Beaudoin B., Nieves-Neira W., Bouillet P., et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005, 7(3):227-238.
77. Tanizaki J., Okamoto I., Fumita S., Okamoto W., Nishio K., Nakagawa K. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 2011, 30(39):4097-4106.
78. Thiesing J.T., Ohno-Jones S., Kolibaba K.S., Druker B.J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000, 96(9):3195-3199.
79. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research 2008, 68(9):3421-3428.
80. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132(5):875-886.
81. Warr M.R., Shore G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Current Molecular Medicine 2008, 8(2):138-147.
82. Westphal D., Dewson G., Czabotar P.E., Kluck R.M. Molecular biology of Bax and Bak activation and action. Biochimica et Biophysica Acta 2011, 1813(4):521-531.
83. Wickenden J.A., Jin H., Johnson M., Gillings A.S., Newson C., Austin M., et al. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 2008, 27(57):7150-7161.
84. Wiggins C.M., Tsvetkov P., Johnson M., Joyce C.L., Lamb C.A., Bryant N.J., et al. BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation. Journal of Cell Science 2011, 124(Pt 6):969-977.
85. Will B., Siddiqi T., Jorda M.A., Shimamura T., Luptakova K., Staber P.B., et al. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 2010, 115(14):2901-2909.
86. Wu J., Rosenbaum E., Begum S., Westra W.H. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. The American Journal of Dermatopathology 2007, 29(6):534-537.
87. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology 2008, 9(4):405-414.
88. Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Science Translational Medicine 2011, 3(99). 99ra86.